Compound: SAQUINAVIR
SMILES: O=C(N[C@H](C(=O)N[C@H]([C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@@H]2CCCC[C@@H]2C1)Cc3ccccc3)CC(=O)N)c4nc5c(cccc5)cc4
InChIKey: QWAXKHKRTORLEM-UGJKXSETSA-N
Synonyms: SAQUINAVIR, 127779-20-8, Fortovase, Saquinavirum, L3JE09KZ2F, Ro 31-8959/000, CHEBI:63621, SCH-52852, DTXSID6044012, Ro-31-8959/000, NSC722663, Butanediamide, N1-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3S-(2(1R*(R*),2S*),3alpha,4aalpha,8aalpha))-, N(1)-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N(2)-(quinolin-2-ylcarbonyl)-L-aspartamide, Saquinivir, saquinaviri mesilas, N(1)-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-phenylbutan-2-yl)-N(2)-(quinolin-2-ylcarbonyl)-L-aspartamide, RefChem:57420, Monomethanesulfonate, Saquinavir, DTXCID4024012, J05AE01, Invirase, (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide, Ro-31-8959, Ro 318959, MFCD00866925, CHEMBL114, C38H50N6O5, (S)-N1-((2S,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-phenylbutan-2-yl)-2-(quinoline-2-carboxamido)succinamide, (2S)-N-[(1S,2R)-3-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-1-benzyl-2-hydroxy-propyl]-2-(quinoline-2-carbonylamino)butanediamide, ROC, Fortovase(TM), Fortovase (TN), (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinolin-2-ylformamido)butanediamide, Butanediamide, N1-[(1S,2R)-3-[(3S,4aS,8aS)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1H)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2S)-, SMR000469157, Saquinavir [USAN], UNII-L3JE09KZ2F, Invirase(TM)(monomesylate), Saquinavir (JAN/USP/INN), Saquinavir?, Sch 52852, HSDB 7161, 1hxb, 2fgu, 2fgv, Saquinavir [USAN:USP:INN:BAN], (2S)-N-[(2S,3R)-4-[(2S,3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1 -phenyl-butan-2-yl]-2-(quinolin-2-ylcarbonylamino)butanediamide, (S)-N-((IS)-I-((1R)-2-((3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydro-2(1H)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide, (S)-N-[(IS)-I-[(1R)-2-[(3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydro-2(1H)-isoquinolyl]-1-hydroxyethyl]phenethyl]-2-quinaldamidosuccinamide, Butanediamide, N1-((1S,2R)-3-((3S,4aS,8aS)-3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-, Saquinavir (Standard), PLCG-SQV, Ro 31 8959, NP-SQV, SAQUINAVIR [MI], SAQUINAVIR [INN], SAQUINAVIR [JAN], Prestwick0_001114, Prestwick1_001114, Prestwick2_001114, Prestwick3_001114, SAQUINAVIR [HSDB], SAQUINAVIR [VANDF], SAQUINAVIR [MART.], SCHEMBL6881, SAQUINAVIR [WHO-DD], SAQUINAVIR [WHO-IP], BIDD:PXR0010, BDBM519, BSPBio_001248, MLS001195635, MLS001304735, BIDD:GT0323, SAQUINAVIR [EMA EPAR], SPBio_003114, BPBio1_001373, GTPL4813, Saquinavir - Bio-X trade mark, SAQUINAVIR [ORANGE BOOK], SCHEMBL28019529, SCHEMBL29357501, SAQUINAVIR [USP IMPURITY], QWAXKHKRTORLEM-UGJKXSETSA-N, HMS2232L04, SAQUINAVIRUM [WHO-IP LATIN], BDBM50213021, EBC-27425, HY-17007R, AKOS000280831, CS-1180, DB01232, FS61498, MRF-0000273, NCGC00091469-02, NCGC00091469-15, (2S)-N-[(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediamide, AC-26377, BS164390, Fortovase; SAQUINAVIR; RO 31-8959, HY-17007, Ro-318959000, AB00514056, NS00007140, D00429, EN300-19767269, Q422654, BRD-K09963420-066-03-4, -phenyl-butan-2-yl]-2-(quinolin-2-ylcarbonylamino)butanediamide, (2S)-N-[(2S,3R)-4-[(2S,3S,4aS,8aS)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinolin-2-yl]-3-hydroxy-1, (3S-(2(1R*(R*),2S*),3I,4athetav,8athetav))-N(sup 1)-(3-(3-(((1,1-Dimethylethyl)amino)carbonyl)octahydro-2(1H)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)butanediamide, (S)-N-((.ALPHA.S)-.ALPHA.-((1R)-2-((3S,4AS,8AS)-3-(TERT-BUTYLCARBAMOYL)OCTAHYDRO-2(1H)-ISOQUINOLYL)-1-HYDROXYETHYL)PHENETHYL)-2-QUINALDAMIDOSUCCINAMIDE, BUTANEDIAMIDE, N(SUP 1)-(3-(3-(((1,1-DIMETHYLETHYL)AMINO)CARBONYL)OCTAHYDRO-2(1H)-ISOQUINOLINYL)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-2-((2-QUINOLINYLCARBONYL)AMINO)-, (3S-(2(1R*(R*),2S*),3.ALPHA.,4A.BETA.,8A.BETA.))-, N-tert.butyl-decahydro -2- [2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl) -L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide, N-tert.butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide, N-tert.butyl-decahydro-2[2(R)-hydroxy-4-phenyl-3-(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide, N~1~-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N~2~-(quinolin-2-ylcarbonyl)-L-aspartamide, N~1~-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-Butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N~2~-(quinoline-2-carbonyl)-L-aspartamide
Theoretical properties:
molecular_formula: C38H50N6O5
molecular_weight: 670.8 g/mol
exact_mass: 670.38426872 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 5
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 13
heavy_atom_count: 49
topological_polar_surface_area: 167 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White crystalline solid
color: White crystalline solid
solubility: Insoluble
vapor_pressure: 2X10-31 mm Hg @ 25 °C /Estimated/
Descriptions:
pubchem: Saquinavir is an aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N2(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease. It has a role as a HIV protease inhibitor and an antiviral drug. It is a member of quinolines and a L-asparagine derivative.
chebi: An aspartic acid derivative obtained by formal condensation of the primary amino group of (2<i>S</i>,3<i>R</i>)-4-[(3<i>S</i>,4a<i>S</i>,8a<i>S</i>)-3-(<em>tert</em>-butylcarbamoyl)octahydroisoquinolin-2(1<em>H</em>)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of <em>N</em><small><sup>2</small></sup>(-quinolin-2-ylcarbonyl)-<small>L</small>-asparagine. An inhibitor of HIV-1 protease.
chembl: SAQUINAVIR is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Saquinavir, sold under the brand name Invirase among others, is an antiretroviral medication used together with other medications to treat or prevent HIV/AIDS. Typically it is used with ritonavir or lopinavir/ritonavir to increase its effect. It is taken by mouth.
Common side effects include nausea, vomiting, diarrhea, and feeling tired. More serious side effects include problems with QT prolongation, heart block, high blood lipids, and liver problems. It appears to be safe in pregnancy. It is in the protease inhibitor class and works by blocking the HIV protease.
Saquinavir was patented in 1988 and first sold in 1995.